DocMorris AG

DocMorris AG: Barclays hält „Hold", Q4‑Ergebnis‑Release am 20. Jan 2026 könnte Kurs und Rating dramatisch beeinflussen – Anleger sollten jetzt genau beobachten.

DocMorris AG reported mixed financial results for the first half of 2025, with significant revenue growth in its prescription segment, but continued financial losses and a negative price-to-earnings ratio.

DocMorris AG’s stock price surges to a six-week high after the company extends its CardLink authorization in Germany, a move seen as a strategic win for the digital health market leader.